Elan Sweetens Deal To Counter $6.6B Takeover Bid
Irish life sciences firm Elan Corp. has sweetened its offer to shareholders to remain invested in the company, offering a percentage of Elan's share of royalties from a new drug if...To view the full article, register now.
Already a subscriber? Click here to view full article